Trial · NCT07882056
SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular Carcinoma
NCT07882056, Phase 2, Not yet recruiting, Peking University Cancer Hospital & Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular Carcinoma. Trials, record NCT07882056. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07882056
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular Carcinoma
- NCT number
- NCT07882056
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 33 participants, estimated
- Lead sponsor
- Peking University Cancer Hospital & Institute
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Stereotactic Body Radiotherapy, Bevacizumab, Iparomlimab and Tuvonralimab
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate per RECIST 1.1 | From the first imaging assessment performed 4-6 weeks after completion of SBRT, repeated every 12 weeks until progression, death, or completion of 2-year follow-up | Proportion of patients achieving complete response or partial response per RECIST 1.1, assessed by investigators. |
| Secondary | Complete Response (CR) per RECIST 1.1 | From the first imaging assessment performed 4-6 weeks after completion of SBRT, repeated every 12 weeks until progression, death, or completion of 2-year follow-up | Proportion of patients achieving complete response (disappearance of all target lesions) per RECIST 1.1, assessed by investigators. |
| Secondary | Disease Control Rate (DCR) per RECIST 1.1 | From the first imaging assessment performed 4-6 weeks after completion of SBRT, repeated every 12 weeks until progression, death, or completion of 2-year follow-up | Proportion of patients achieving complete response, partial response, or stable disease (CR + PR + SD) per RECIST 1.1, assessed by investigators. |
| Secondary | Time to Response (TOR) | From enrollment to the first documented response (RECIST 1.1 and mRECIST), up to 2 years | Time from enrollment to the first documented tumor response per RECIST 1.1 and mRECIST. |
| Secondary | Duration of Response (DOR) | From first documented response to disease progression or death from any cause, up to 2 years | Time from first documented response until disease progression or death from any cause, per RECIST 1.1 and mRECIST. |
| Secondary | Local Control (LC) | From enrollment to first progression within the irradiated volume (within the 80% isodose line), assessed every 12 weeks, up to 2 years | Time from enrollment to first progression within the high-dose irradiated region (within the 80% isodose line), per RECIST 1.1 and mRECIST. |
| Secondary | Progression-Free Survival (PFS) | From enrollment to disease progression or death from any cause, up to 2 years | Time from enrollment to disease progression or death from any cause, per RECIST 1.1 and mRECIST. |
| Secondary | Time to Progression (TTP) | From enrollment to disease progression, up to 2 years | Time from enrollment to disease progression, per RECIST 1.1 and mRECIST. |
| Secondary | Overall Survival (OS) | From enrollment to death from any cause, up to 2 years of follow-up | Time from enrollment until death from any cause. |
| Secondary | Incidence of Adverse Events | From first dose of study treatment until 30 days after the last dose for adverse events and serious adverse events; safety follow-up visit 6 weeks after the last dose | Incidence, severity (CTCAE v6.0), relatedness, and outcome of adverse events and serious adverse events, including incidence of grade 3 or higher events, treatment-related events, fatal events, and events leading to treatment discontinuation. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07882056
GET https://conductscience.org/api/trials/v1/NCT07882056/registered